In this pilot study the investigators will perform a double-blind randomized trial of
intranasal oxytocin on measures of cardiac refractoriness, among individuals who are
undergoing clinically indicated catheter ablation procedures for paroxysmal atrial
fibrillation. The investigators seek to enroll 20 patients for this study, for the purpose of
estimating effect sizes for a larger future study.